Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...

Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending ...

N'inyuma yo kwibaruka, "nategerezwa gukomeza guhabwa amaraso, niko uyu muvyeyi w'imyaka 25 avuga, aho igihe kimwe yabwirizwa guhabwa ayo maraso kandi ariko aronsa agahinja yaheruka kwibaruka. Ico ...